Using the blockchain to enable transparent and auditable processing of personal data in cloud- based services: Lessons from the Privacy-Aware Cloud Ecosystems (PACE) project

The architecture of cloud-based services is typically opaque and intricate. As a result, data subjects cannot exercise adequate control over their personal data, and overwhelmed data protection authorities must spend their limited resources in costly forensic efforts to ascertain instances of non-compliance. To address these data protection challenges, a group of computer scientists and socio-legal scholars joined forces in the Privacy-Aware Cloud Ecosystems (PACE) project to design a blockchain-based privacy-enhancing technology (PET). This article presents the fruits of this collaboration, highlighting the capabilities and limits of our PET, as well as the challenges we encountered during our interdisciplinary endeavour. In particular, we explore the barriers to interdisciplinary collaboration between law and computer science that we faced, and how these two fields’ different expectations as to what technology can do for data protection law compliance had an impact on the project's development and outcome. We also explore the overstated promises of techno-regulation, and the practical and legal challenges that militate against the implementation of our PET: most industry players have no incentive to deploy it, the transaction costs of running it make it prohibitively expensive, and there are significant clashes between the blockchain's decentralised architecture and GDPR's requirements that hinder its deployability. We share the insights and lessons we learned from our efforts to overcome these challenges, hoping to inform other interdisciplinary projects that are increasingly important to shape a data ecosystem that promotes the protection of our personal data

PARROT: Interactive privacy-aware internet of things application design tool

Internet of Things (IoT) applications typically collect and analyse personal data that is categorised as sensitive or special category of personal data. These data are subject to a higher degree of protection under data privacy laws. Regardless of legal requirements to support privacy practices, such as in Privacy by Design (PbD) schemes, these practices are not yet commonly followed by software developers. The difficulty of developing privacy-preserving applications emphasises the importance of exploring the problems developers face to embed privacy techniques, suggesting the need for a supporting tool. An interactive IoT application design tool - PARROT (PrivAcy by design tool foR inteRnet Of Things) - is presented. This tool helps developers to design privacy-aware IoT applications, taking account of privacy compliance during the design process and providing real-time feedback on potential privacy violations. A user study with 18 developers was conducted, comprising a semi-structured interview and a design exercise to understand how developers typically handle privacy within the design process. Collaboration with a privacy lawyer was used to review designs produced by developers to uncover privacy limitations that could be addressed by developing a software tool. Based on the findings, a proof-of-concept prototype of PARROT was implemented and evaluated in two controlled lab studies. The outcome of the study indicates that IoT applications designed with PARROT addressed privacy concerns better and managed to reduce several of the limitations identified. From a privacy compliance perspective, PARROT helps developers to address compliance requirements throughout the design and testing process. This is achieved by incorporating privacy specific design features into the IoT application from the beginning rather than retrospectively

COM-PACE: Compliance-Aware Cloud Application Engineering Using Blockchain

The COVID19 Pandemic has highlighted our dependence on online services (from government, e-commerce/retail, and entertainment), often hosted over external cloud computing infrastructure. The users of these services interact with a web interface rather than the larger distributed service provisioning chain that can involve an interlinked group of providers. The data and identity of users are often provided to service provider who may share it (or have automatic sharing agreement) with backend services (such as advertising and analytics). We propose the development of compliance-aware cloud application engineering, which is able to improve transparency of personal data use -- particularly with reference to the European GDPR regulation. Key compliance operations and the perceived implementation challenges for the realization of these operations in current cloud infrastructure are outlined

Skeletal diseases caused by mutations in PTH1R show aberrant differentiation of skeletal progenitors due to dysregulation of DEPTOR

Alterations in the balance between skeletogenesis and adipogenesis is a pathogenic feature in multiple skeletal disorders. Clinically, enhanced bone marrow adiposity in bones impairs mobility and increases fracture risk, reducing the quality of life of patients. The molecular mechanism that underlies the balance between skeletogenesis and adipogenesis is not completely understood but alterations in skeletal progenitor cells’ differentiation pathway plays a key role. We recently demonstrated that parathyroid hormone (PTH)/PTH-related peptide (PTHrP) control the levels of DEPTOR, an inhibitor of the mechanistic target of rapamycin (mTOR), and that DEPTOR levels are altered in different skeletal diseases. Here, we show that mutations in the PTH receptor-1 (PTH1R) alter the differentiation of skeletal progenitors in two different skeletal genetic disorders and lead to accumulation of fat or cartilage in bones. Mechanistically, DEPTOR controls the subcellular localization of TAZ (transcriptional co-activator with a PDZ-binding domain), a transcriptional regulator that governs skeletal stem cells differentiation into either bone and fat. We show that DEPTOR regulation of TAZ localization is achieved through the control of Dishevelled2 (DVL2) phosphorylation. Depending on nutrient availability, DEPTOR directly interacts with PTH1R to regulate PTH/PTHrP signaling or it forms a complex with TAZ, to prevent its translocation to the nucleus and therefore inhibit its transcriptional activity. Our data point DEPTOR as a key molecule in skeletal progenitor differentiation; its dysregulation under pathologic conditions results in aberrant bone/fat balance

Design and rationale of a multicentre, randomised, double-blind, placebo-controlled clinical trial to evaluate the effect of vitamin D on ventricular remodelling in patients with anterior myocardial infarction: the VITamin D in Acute Myocardial Infarction (VITDAMI) trial

Introduction:Decreased plasma vitamin D (VD) levels are linked to cardiovascular damage. However, clinical trials have not demonstrated a benefit of VD supplements on left ventricular (LV) remodelling. Anterior ST-elevation acute myocardial infarction (STEMI) is the best human model to study the effect of treatments on LV remodelling. We present a proof-of-concept study that aims to investigate whether VD improves LV remodelling in patients with anterior STEMI. Methods and analysis:The VITamin D in Acute Myocardial Infarction (VITDAMI) trial is a multicentre, randomised, double-blind, placebo-controlled trial. 144 patients with anterior STEMI will be assigned to receive calcifediol 0.266 mg capsules (Hidroferol SGC)/15 days or placebo on a 2:1 basis during 12 months. Primary objective:to evaluate the effect of calcifediol on LV remodelling defined as an increase in LV end-diastolic volume >= 10\% (MRI). Secondary objectives:change in LV end-diastolic and end-systolic volumes, ejection fraction, LV mass, diastolic function, sphericity index and size of fibrotic area; endothelial function; plasma levels of aminoterminal fragment of B-type natriuretic peptide, galectin-3 and monocyte chemoattractant protein-1; levels of calcidiol (VD metabolite) and other components of mineral metabolism (fibroblast growth factor-23 (FGF-23), the soluble form of its receptor klotho, parathormone and phosphate). Differences in the effect of VD will be investigated according to the plasma levels of FGF-23 and klotho. Treatment safety and tolerability will be assessed. This is the first study to evaluate the effect of VD on cardiac remodelling in patients with STEMI. Ethics and dissemination: This trial has been approved by the corresponding Institutional Review Board (IRB) and National Competent Authority (Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS)). It will be conducted in accordance with good clinical practice (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use-Good Clinical Practice (ICH-GCP)) requirements, ethical principles of the Declaration of Helsinki and national laws. The results will be submitted to indexed medical journals and national and international meetings.The VITDAMI trial is an investigator initiated study, sponsored by the Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS-FJD). Funding has been obtained from Fondo de Investigaciones Sanitarias (PI14/01567; http://www.isciii.es/) and Spanish Society of Cardiology (http://secardiologia.es/). In addition, the study medication has been provided freely by the pharmaceutical Company FAES FARMA S.A. (Leioa, Vizcaya, Spain; http://faesfarma.com/). This company was the only funder who collaborated in study design (IG-H).S

Making Waves : Collaboration in the time of SARS-CoV-2-rapid development of an international co-operation and wastewater surveillance database to support public health decision-making

The presence of SARS-CoV-2 RNA in wastewater was first reported in March 2020. Over the subsequent months, the potential for wastewater surveillance to contribute to COVID-19 mitigation programmes has been the focus of intense national and international research activities, gaining the attention of policy makers and the public. As a new application of an established methodology, focused collaboration between public health practitioners and wastewater researchers is essential to developing a common understanding on how, when and where the outputs of this non-invasive community-level approach can deliver actionable outcomes for public health authorities. Within this context, the NORMAN SCORE "SARS-CoV-2 in sewage" database provides a platform for rapid, open access data sharing, validated by the uploading of 276 data sets from nine countries to-date. Through offering direct access to underpinning meta-data sets (and describing its use in data interpretation), the NORMAN SCORE database is a resource for the development of recommendations on minimum data requirements for wastewater pathogen surveillance. It is also a tool to engage public health practitioners in discussions on use of the approach, providing an opportunity to build mutual understanding of the demand and supply for data and facilitate the translation of this promising research application into public health practice. (C) 2021 Elsevier Ltd. All rights reserved.Peer reviewe

Herramientas de aprendizaje para estudiantes de secundaria: Aplicación de la Genética a una situación real

Depto. de Genética, Fisiología y MicrobiologíaFac. de Ciencias BiológicasFALSEsubmitte

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality